Sarcoma  >>  gemcitabine  >>  Phase 2
Welcome,         Profile    Billing    Logout  

80 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
gemcitabine / Generic mfg.
NCT02511132: A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma

Completed
2b
22
US
Vigil, formerly known as FANG™, bi-shRNAfurin and GMCSF Autologous Tumor Cell Immunotherapy, Temozolomide, TEMODAR, Irinotecan, CAMPTOSAR, Gemcitabine, GEMZAR, Docetaxel, TAXOTERE
Gradalis, Inc.
Ewing's Sarcoma
11/18
12/20
NCT00004066: Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma

Completed
2
82
US
filgrastim, docetaxel, gemcitabine hydrochloride
Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI)
Ovarian Cancer, Sarcoma, Small Intestine Cancer
10/03
10/03
NCT00003316: Gemcitabine in Treating Patients With Recurrent or Refractory Cancer of the Uterus

Terminated
2
US, Canada
gemcitabine hydrochloride
Gynecologic Oncology Group, National Cancer Institute (NCI)
Sarcoma
04/04
 
NCT00027703: Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma

Checkmark P2 data (Mesothelioma)
Jun 2012 - Jun 2012: P2 data (Mesothelioma)
Completed
2
106
US
gemcitabine hydrochloride, dFdC, difluorodeoxycytidine hydrochloride, gemcitabine, Gemzar, cisplatin, CACP, CDDP, CPDD, DDP, bevacizumab, anti-VEGF humanized monoclonal antibody, anti-VEGF monoclonal antibody, Avastin, rhuMAb VEGF, placebo, PLCB, laboratory biomarker analysis
National Cancer Institute (NCI)
Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Localized Malignant Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma
05/06
 
NCT00101127: Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma

Completed
2
US
filgrastim, pegfilgrastim, docetaxel, gemcitabine hydrochloride
Gynecologic Oncology Group, National Cancer Institute (NCI)
Sarcoma
07/06
 
NCT00134641: Study of Gemcitabine and Vinorelbine in Soft Tissue Sarcomas

Completed
2
40
US
gemcitabine, vinorelbine
Dana-Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital
Sarcoma, Soft Tissue
06/07
06/07
NCT00031629: Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus

Completed
2
51
US
Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Filgrastim, Filgrastim XM02, Filgrastim-sndz, G-CSF, Neupogen, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, rG-CSF, Tbo-filgrastim, Tevagrastim, Zarxio, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemzar, LY-188011, LY188011, Pegfilgrastim, Filgrastim SD-01, filgrastim-SD/01, HSP-130, Neulasta, Neulastim, Pegfilgrastim Biosimilar HSP-130, SD-01, SD-01 sustained duration G-CSF
Gynecologic Oncology Group, National Cancer Institute (NCI)
Recurrent Uterine Corpus Sarcoma, Uterine Corpus Leiomyosarcoma
07/07
 
NCT00068393: Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma

Completed
2
39
US
Doxorubicin, Adriamycin, Rubex, Gemcitabine, G-CSF (granulocyte-colony stimulating factor), Neupogen, Filgrastim, Neulasta, pegfilgrastim
Eastern Cooperative Oncology Group, National Cancer Institute (NCI)
Metastatic Renal Cell Carcinoma, Renal Cell Carcinoma With Sarcomatoid Features
06/09
05/11
NCT00860015: Alimta Plus Gemcitabine for Advanced Sarcoma

Completed
2
12
US
Alimta, Pemetrexed, Gemcitabine, Gemzar
Columbia University
Sarcoma, Soft Tissue
08/09
04/12
NCT00407433: Clinical Studies of Gemcitabine-Oxaliplatin

Completed
2
156
Europe
Gemcitabine (Gemzar®), Oxaliplatin (Eloxatin®)
Gustave Roussy, Cancer Campus, Grand Paris
Medulloblastoma, Central Nervous System Tumors, Neuroblastoma, Osteosarcoma
 
 
NCT00073983: Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma

Completed
2
54
US
filgrastim, pegfilgrastim, docetaxel, gemcitabine hydrochloride, microarray analysis, laboratory biomarker analysis, pharmacokinetic study
Sarcoma Alliance for Research through Collaboration
Sarcoma
01/10
12/10
NCT00227669: Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma

Completed
2
90
Europe
docetaxel, gemcitabine hydrochloride
UNICANCER
Sarcoma
02/10
08/12
NCT00359333: Phase II Trial of Locally Advanced/Metastatic Soft Tissue Sarcoma or Advanced/Metastatic Malignant GIST

Completed
2
58
RoW
Gemcitabine , Docetaxel
National Health Research Institutes, Taiwan, Mackay Memorial Hospital, Tri-Service General Hospital, China Medical University Hospital, Kaohsiung Veterans General Hospital., Taichung Veterans General Hospital, Buddhist Tzu Chi General Hospital
Sarcoma, Malignant Gastrointestinal Stromal Tumor
04/10
03/11
NCT00114218: Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer

Completed
2
28
US
Gemcitabine Hydrochloride, dFdC, dFdCyd, Docetaxel, TXT
Gynecologic Oncology Group, National Cancer Institute (NCI)
Recurrent Uterine Corpus Sarcoma, Uterine Carcinosarcoma
07/10
 
NCT00807261: Weekly Docetaxel and Fixed-Dose Rate Gemcitabine Combination Chemotherapy

Unknown status
2
30
NA
Gemcitabine and Docetaxel
Asan Medical Center, Severance Hospital, Korea University Anam Hospital, Samsung Medical Center
Sarcoma
09/10
09/10
GVPS, NCT01192633: Gemcitabine,Vincristine and Cisplatin as Second Line Combination Therapy in Patients With Sarcoma

Unknown status
2
40
RoW
GVP
Fudan University
Sarcoma, Chemotherapy
01/11
01/11
NCT00282087: Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma

Completed
2
47
US
gemcitabine, docetaxel, doxorubicin
Sarcoma Alliance for Research through Collaboration
Leiomyosarcoma, Uterine Neoplasm
01/12
01/12
2012-001106-26: TRIAL PHASE II MULTICENTER FOR CANCER PATIENTS DIAGNOSED WITH OSTEOSARCOMA WITH METASTASIS WHO HAVE ALREADY BEEN TREATED PREVIOUSLY ESTUDIO FASE II MULTICENTRICO PARA PACIENTES DIAGNOSTICADOS DE CANCER TIPO OSTEOSARCOMA CON METASTASIS QUE YA HAN SIDO TRATADOS PREVIAMENTE

Ongoing
2
33
Europe
Concentrate and solvent for solution for infusion, Oral solution, GEMCITABINE, RAPAMUNE
JAVIER MARTÍN BROTO, Dirección General de Farmacia y Productos Sanitarios del Ministerio de Sanidad, Política Social e Igualdad
Patients diagnosed with metastatic osteosarcoma cancer types that have been treated with chemotherapy and have active disease that permits to receive this treatment combination. Pacientes diagnosticados de osteosarcoma metastásico que han sido tratados con quimioterapia y tienen enfermedad que permite recibir esta combinación de tratamiento., Patients with metastatic osteosarcoma cancer that have been treated with standard chemotherapy and have active disease requiring treatment. Pacientes diagnosticados de cáncer tipo osteosarcoma metastásico que han sido tratados y tienen enfermedad activa, necesitando recibir tratamiento para su enfermedad., Diseases [C] - Cancer [C04]
 
 
NCT00189137: Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in the Treatment Soft Tissue Sarcoma

Completed
2
84
US
ifosfamide and doxorubicin vs gemcitabine and docetaxel
University of Michigan Rogel Cancer Center
Sarcoma, Soft Tissue
11/12
10/15
NCT00556049: Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma

Checkmark ASCO-GU 2015
Feb 2015 - Feb 2015: ASCO-GU 2015
Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Completed
2
72
US
Gemcitabine, Gemzar, Sunitinib, Sutent
Massachusetts General Hospital, Pfizer, Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute
Renal Cell Carcinoma, Neoplasm Metastases
12/13
12/14
NCT00887809: Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes

Completed
2
47
US
gemcitabine, docetaxel, bevacizumab
Memorial Sloan Kettering Cancer Center, Genentech, Inc.
Sarcoma, Leiomyosarcoma, Malignant Fibrous, Histiocytoma, Angiosarcoma
10/14
11/14
GEIS-29, NCT02429973: Trial With Gemcitabine and Rapamycin in Second Line of Metastatic Osteosarcoma

Completed
2
33
Europe
Gemcitabine plus rapamycin
Broto, Javier Martín, M.D.
Osteosarcoma
12/14
04/15
NCT01812018: Endostar + GT in Pulmonary Metastases of Soft Tissue Sarcoma

Unknown status
2
30
RoW
Endostar, Recombinant Human Endostatin Injection, Gemcitabine, Docetaxel
Peng Yuan
Soft Tissue Sarcoma
04/15
10/15
NCT01574716 / 2012-001399-12: Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation

Completed
2
209
Europe, US, RoW
MORAb-004, Gemcitabine, Docetaxel, Placebo
Morphotek
Metastatic Soft Tissue Sarcoma
08/15
08/16
2005-001709-24: Estudio en fase II, abierto, multicéntrico, prospectivo y aleatorizado, con DTIC o la combinación de Gemcitabina y DTIC en sarcomas de partes blandas avanzados del adulto

Ongoing
2
110
Europe
gemcitabina, M01/142, Gemzar, Gemzar
Grupo Español de Investigación en Sarcomas (GEIS)
Sarcomas de partes blandas
 
 
NCT00496587: Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma

Completed
2
34
US
Capecitabine, Xeloda, Gemcitabine, Gemzar, Gemcitabine Hydrochloride, Bevacizumab, Avastin, Anti-VEGF monoclonal antibody, rhuMAb-VEGF
M.D. Anderson Cancer Center, Eli Lilly and Company
Renal Cell Carcinoma, Kidney Cancer
05/16
05/16
2009-017261-32: Phase II randomized clinical trial of Pazopanib alone and Pazopanib plus Gemcitabine in relapsed or metastatic soft tissue sarcoma

Completed
2
90
Europe
Gemcitabine, Gemcitabine, Film-coated tablet, Concentrate for solution for infusion, Votrient 400 mg film-coated tablets, Votrient 200 mg film-coated tablets
Martin-Luther-Universität Halle-Wittenberg, GlaxoSmithKline GmbH & Co.KG, Aspen Bad Oldesloe GmbH, Martin Luther Universität Halle (Saale)
Relapsed or metastatic soft tissue sarcoma, Relapsed or metastatic soft tissue sarcoma, Diseases [C] - Cancer [C04]
 
 
NCT02303262: SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma

Completed
2
20
US
Mocetinostat, Gemcitabine
Sarcoma Alliance for Research through Collaboration
Metastatic Leiomyosarcoma
12/16
12/16
NCT02448537: A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas

Completed
2
42
US
PM01183, lurbinectedin, Doxorubicin, Hydroxydaunomycin Hydrochloride, Adriamycin, Hydroxydoxorubicin Hydrochloride, Gemcitabine, Gemzar
Massachusetts General Hospital, Dana-Farber Cancer Institute, PharmaMar
Metastatic Sarcoma
02/17
04/19
TAUL, NCT02249702 / 2009-016017-24: Activity of Trabectedin or Gemcitabine + Docetaxel in Uterine Leiomyosarcoma

Completed
2
168
Europe
gemcitabine + docetaxel, Gemzar, Taxotere, trabectedin, Yondelis
Mario Negri Institute for Pharmacological Research, PharmaMar
Leiomyosarcoma
04/17
04/17
NCT01442662: Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patient With Metastatic or Relapsed Uterine

Completed
2
106
Europe
pazopanib + gemcitabine
UNICANCER
Leiomyosarcoma
03/18
05/19
OsteoREC2015, NCT02718482 / 2015-004762-28: Phase II Trial for the Treatment of Relapsed Osteosarcoma

Terminated
2
7
Europe
Gemcitabine and Docetaxel, Ifosfamide, High doses ifosfamide
Italian Sarcoma Group
OSTEOSARCOMA
01/19
01/19
NCT03468075: Gemcitabine Plus Ascorbate for Sarcoma in Adults

Terminated
2
10
US
Ascorbate, Ascorbic Acid, Vitamin C, Pharmacological ascorbate, Gemcitabine, Gemzar
Mohammed Milhem, MBBS, University of Iowa Adolescent and Young Adult (AYA) Cancer Program, St. Baldrick's Foundation, University of Iowa
Sarcoma, Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma, Metastatic Bone Tumor, Bone Sarcoma
04/19
10/20
NCT01593748: A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma

Completed
2
90
US
Gemcitabine and Pazopanib, Gemcitabine and Docetaxel
Medical University of South Carolina, Novartis
Sarcoma
04/19
04/19
NCT01532687: Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma

Completed
2
54
US
Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Gemcitabine Hydrochloride, Difluorodeoxycytidine Hydrochloride, FF 10832, FF-10832, FF10832, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Laboratory Biomarker Analysis, Pazopanib, GW786034, Pazopanib Hydrochloride, GW786034B, Votrient, Placebo Administration
OHSU Knight Cancer Institute, Novartis Pharmaceuticals, Oregon Health and Science University
Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor, Adult Epithelioid Hemangioendothelioma, Adult Epithelioid Sarcoma, Adult Extraskeletal Myxoid Chondrosarcoma, Adult Extraskeletal Osteosarcoma, Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Malignant Peripheral Nerve Sheath Tumor, Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Adult Undifferentiated Pleomorphic Sarcoma, Malignant Adult Hemangiopericytoma, Recurrent Adult Soft Tissue Sarcoma, Sarcoma, Stage III Adult Soft Tissue Sarcoma AJCC v7, Stage IV Adult Soft Tissue Sarcoma AJCC v7
10/19
10/19
NCT01164228: Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery

Completed
2
87
US
Gemcitabine, 2'-Deoxy-2', 2'-difluorocytidine monohydrochloride, Gemzar, Sunitinib, SU011248 L-Malate salt, SU010398, PHA-290940AD, Sutent, SU011248
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Kidney Cancer
03/20
11/21
2020-000741-13: Trial assessing the activity of TrabectedIn vs gemCitabine in patients with advanced LEiomyosarcoma Studio sull’attività della Trabectedina vs Gemcitabina in pazienti con leiomiosarcoma avanzato pretrattati c

Not yet recruiting
2
100
Europe
Trabectedina, Gemcitabina, [trabectedina], [Gemcitabina], Powder for infusion, Concentrate for solution for infusion, Yondelis, GEMCITABINA ACCORD - 100 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 2 ML
ITALIAN SARCOMA GROUP, Pharmamar
metastatic or locally advanced Leiomyosarcoma pretreated with conventional chemotherapy leiomiosarcoma metastatico o localmente avanzato pretrattati con chemioterapia convenzionale, advanced Leiomyosarcoma leiomiosarcoma avanzato, Diseases [C] - Cancer [C04]
 
 
ChiCTR1800016587: Comparison of efficacy between GD and IE as second-line chemotherapy regimens in advanced soft tissue sarcoma: a phase II randomized controlled trial

Not yet recruiting
2
266
 
Gemcitabine with Docetaxel ;Ifosfamide with Etoposide
West China Hospital, Sichuan University; West China Hospital, Sichuan University, Self financing
soft tissue sarcoma
 
 
2018-003835-31: Targeting ATR in soft-tissue sarcomas: a randomized phase II study. TARSARC study Ciblage d’ATR dans les sarcomes des tissus mous : une étude randomisée de phase II. Etude TARSARC

Not yet recruiting
2
72
Europe
Berzosertib, GEMCITABINE, M6620, Solution for infusion, GEMCITABINE
Institut Bergonié, Merck Healthcare KGaA
Locally advanced/unresectable and/or metastatic soft-tissue leiomyosarcomas Léiomyosarcomes localement avancés et/ou métastatiques, Locally advanced/unresectable and/or metastatic soft-tissue leiomyosarcomas Léiomyosarcomes localement avancés et/ou métastatiques, Diseases [C] - Cancer [C04]
 
 
EAGLES, NCT03536780: Avelumab in Combination With Gemcitabine in Advanced Leiomyosarcoma as a Second-line Treatment

Recruiting
2
38
RoW
Avelumab and Gemcitabine
Gachon University Gil Medical Center, Merck KGaA, Darmstadt, Germany, Chong Kun Dang Pharmaceutical Corp.
Leiomyosarcoma Metastatic
12/21
12/22
NCI-2014-00620, NCT02101775: Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Active, not recruiting
2
124
Canada, US, RoW
Adavosertib, AZD-1775, AZD1775, MK-1775, MK1775, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Laboratory Biomarker Analysis, Pharmacological Study, Placebo Administration, Questionnaire Administration
National Cancer Institute (NCI)
Ovarian Brenner Tumor, Ovarian Carcinosarcoma, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Serous Surface Papillary Adenocarcinoma, Ovarian Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
02/22
02/25
NCT03810976: A Study of Eribulin With Gemcitabine in Patients With Advanced Liposarcoma or Leiomyosarcoma

Completed
2
37
RoW
Eribulin, gemcitabine
Yonsei University
Sarcoma
05/22
05/22
NCT04906876: A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas

Withdrawn
2
0
US
Gemcitabine, Docetaxel, 9-ING-41
Brown University, Actuate Therapeutics Inc.
Sarcoma, Soft Tissue Sarcoma, Metastatic Sarcoma, Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, Leiomyosarcoma, Liposarcoma, Angiosarcoma, Synovial Sarcoma, Rhabdomyosarcoma, Spindle Cell Sarcoma, High Grade Sarcoma, Bone Sarcoma
07/22
07/25
NCT03449901: ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer

Completed
2
98
US
pegylated arginine deiminase, ADI-PEG 20, Gemcitabine, Gemzar, Docetaxel, Taxotere, Tumor biopsy, Research blood draw
Washington University School of Medicine, National Institutes of Health (NIH), National Cancer Institute (NCI)
Soft Tissue Sarcoma
07/22
07/22
NCT03912818: Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

Terminated
2
7
US
Carboplatin, Carboplat, Carboplatino, Carbosol, Paraplatin, Paraplatine, Cisplatin, Abiplatin, Briplatin, Cis-platinum, Cismaplat, Citoplatino, Plastistil, Platinol, Cystectomy, Doxorubicin, Adriablastin, Hydroxyl Daunorubicin, Rubex, Durvalumab, Imfinzi, MEDI-4736, Gemcitabine, Difluorodeoxycytidine, Gemzar, Methotrexate, Abitrexate, Amethopterin, Brimexate, Methotrexate Methylaminopterin, Metotrexato, Vinblastine, Vincaleucoblastine, Vinblastine Sulfate, vincaleukoblastine, sulfate
Stanford University, AstraZeneca
Bladder Adenocarcinoma, Bladder Mixed Adenocarcinoma, Bladder Squamous Cell Carcinoma, Bladder Urothelial Carcinoma, Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma With Giant Cells, Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation, Infiltrating Bladder Urothelial Carcinoma With Trophoblastic Differentiation, Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant, Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant, Infiltrating Bladder Urothelial Carcinoma, Nested Variant, Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant
08/22
08/22
NCT02203760 / 2012-003810-15: Pazopanib vs. Pazopanib Plus Gemcitabine

Active, not recruiting
2
58
Europe
Pazopanib plus Gemcitabine, Votrient and Gemzar, Pazopanib, Votrient
North Eastern German Society of Gynaecological Oncology, Novartis Pharmaceuticals, medac GmbH
Leiomyosarcoma or Carcinosarcoma
12/24
12/24
NCT04183062: BIO-11006 for Osteosarcoma and Ewing's Sarcoma Lung Metastases

Active, not recruiting
2
10
US
Chemotherapy (gemcitabine & docetaxel) plus BIO-11006
Nicklaus Children's Hospital f/k/a Miami Children's Hospital
Osteosarcoma Metastatic, Ewing's Sarcoma Metastatic
11/23
11/24
PROACH, NCT03742193: Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapy

Active, not recruiting
2
43
RoW
Apatinib, VEGFR Inhibitor, GD regimen, Chemotherapy
Ruijin Hospital
Osteosarcoma, Pulmonary Metastases, Apatinib
11/23
12/23
NCT02945800: Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma

Active, not recruiting
2
59
US
nab-Paclitaxel, Abraxane, Gemcitabine, Gemzar
H. Lee Moffitt Cancer Center and Research Institute, National Pediatric Cancer Foundation
Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Soft Tissue Sarcoma
01/24
12/24
NCT04727242: CytoreductiveSurgery & HIPEC w/Gemcitabine+Chemotherapy w/Dacarbazine in Uterine Leiomyosarcoma

Recruiting
2
25
US
Gemcitabine, Gemzar, Infugem, difluorodeoxycytidine hydrochloride, Dacarbazine, Dimethyl (triazeno) imidazolecarboxamide, Dacarbazine - DTIC, Biocarbazine, Cytoreductive Surgery, Functional Assessment of Cancer Therapy (FACT) G questionnaire, Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Scan, Gadolinium
Kristen Ganjoo
LMS - Leiomyosarcoma, Uterine Leiomyosarcoma
01/25
01/25
NCT05275426: A Study of LY2880070 and Gemcitabine in People With Ewing Sarcoma,Ewing-Like Sarcoma, and Desmoplastic Small Round Cell Tumor

Recruiting
2
24
US
LY2880070, Gemcitabine
Memorial Sloan Kettering Cancer Center
Ewing Sarcoma, Ewing-Like Sarcoma
03/25
03/25
NCT05481645: Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.

Recruiting
2
79
RoW
TQB2450 injection, Anlotinib Hydrochloride Capsule, Carboplatin Injection, Paclitaxel Injection, Doxorubicin Hydrochloride Injection, Gemcitabine Hydrochloride Injection, Docetaxel injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Endometrial Cancer, Sarcoma of Uterus
06/24
12/24
ISG-ARTICLE, NCT04383119: Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma

Recruiting
2
100
Europe
Trabectedin, Trabectedin arm, Gemcitabine, Gemcitabine arm, No Intervention: Observational Cohort
Italian Sarcoma Group, PharmaMar
Leiomyosarcoma of Ovary, Soft Tissue Sarcoma
06/24
09/24
TAGGED, NCT04535271: Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Leiomyosarcoma

Recruiting
2
80
US
Trabectedin, Gemcitabine, Dacarbazine
Sarcoma Oncology Research Center, LLC
Leiomyosarcoma
09/24
12/24
TARSARC, NCT04807816: Targeting ATR in Soft-tissue Sarcomas

Recruiting
2
72
Europe
Association of berzosertib with gemcitabine, Experimental, Gemcitabine, Control
Institut Bergonié, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Leiomyosarcoma, Adult
10/24
04/26
Actuate 1801, NCT03678883: 9-ING-41 in Patients With Advanced Cancers

Active, not recruiting
2
350
Europe, Canada, US
9-ING-41, Gemcitabine - 21 day cycle, Gemzar, Doxorubicin., Doxil, Adriamycin, Lomustine, CCNU, Gleostine, Carboplatin., Paraplatin, Nab paclitaxel., Abraxane, Protein-bound paclitaxel, Nanoparticle albumin-bound paclitaxel, Paclitaxel., Taxol, Gemcitabine - 28 day cycle, Irinotecan, Camptosar
Actuate Therapeutics Inc.
Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
11/24
11/25
ChiCTR2100053490: A phase 2 study of Surufatinib in patients after first line standard chemotherapy or Anlotinib treatment failure of soft tissue sarcoma

Recruiting
2
64
 
Surufatinib+Gemcitabine ;Surufatinib
Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University, Part of self-raised, part of Hutchison Whampoa Pharmaceuticals (Shanghai) Co., Ltd.
Soft Tissue Sarcoma
 
 
NCT05116800: Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma

Withdrawn
2
0
US
Gemcitabine, 9-ING-41, Docetaxel
Brown University, Actuate Therapeutics
Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, Leiomyosarcoma, Liposarcoma, Angiosarcoma, Synovial Sarcoma, Rhabdomyosarcoma, Spindle Cell Sarcoma, High Grade Sarcoma, Bone Sarcoma, Osteosarcoma, Ewing Sarcoma of Bone
08/25
08/30
GALLANT, NCT04535713: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma

Recruiting
2
260
US
Gemcitabine, Gemzar, Doxorubicin, Adriamycin, Docetaxel, Taxotere, Nivolumab, Opdivo
Sarcoma Oncology Research Center, LLC
Sarcoma
09/25
12/25
SeliSarc, NCT06114004: Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma

Recruiting
2
88
Europe
Selinexor 20 MG, KPT-330, Gemcitabine
Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas
Sarcoma,Soft Tissue
05/26
05/26
PROMIS, NCT06114225: Pulmonary Resectable Osteosarcoma Treated by Metastasectomy and Pre-operative Immunotherapy and Stereotactic Body Radiotherapy (): a Prospective Clinical Trial

Recruiting
2
43
RoW
metastasectomy and pre-operative immunotherapy (gemcitabine and penpulimab ) and stereotactic body radiotherapy
Ruijin Hospital
Osteosarcoma
09/26
12/26
NCT02364713: MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer

Active, not recruiting
2
66
US
Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, FF 10832, FF-10832, FF10832, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Laboratory Biomarker Analysis, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter, MV-NIS, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pegylated Liposomal Doxorubicin Hydrochloride, ATI-0918, Caelyx, Dox-SL, Doxil, Doxilen, Doxorubicin HCl Liposomal, Doxorubicin HCl Liposome, Doxorubicin Hydrochloride Liposome, Duomeisu, Evacet, LipoDox, Lipodox 50, Liposomal Adriamycin, Liposomal Doxorubicin Hydrochloride, Liposomal-Encapsulated Doxorubicin, Pegylated Doxorubicin HCl Liposome, S-Liposomal Doxorubicin, Stealth Liposomal Doxorubicin, TLC D-99, Quality-of-Life Assessment, Quality of Life Assessment, Topotecan Hydrochloride, Hycamptamine, Hycamtin, SKF S-104864-A, Topotecan HCl, topotecan hydrochloride (oral)
Mayo Clinic, National Cancer Institute (NCI)
Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Carcinosarcoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
03/27
02/28
GemTax, NCT01879085: Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma

Completed
1b/2
37
US
Docetaxel, Taxotere, Gemcitabine, Gemzar, Vorinostat, Zolinza, Pegfilgrastim, Neulasta
Melissa Burgess, MD, Merck Sharp & Dohme LLC
Sarcoma
04/21
04/21
NCT01491594: Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia

Terminated
1/2
1
US
Eltrombopag, Promacta
Duke University, GlaxoSmithKline
Sarcoma, Soft Tissue, Osteosarcoma, Neoplasms, Connective and Soft Tissue
03/13
03/13
NCT01684449: Gemcitabine Plus Rapamycin Versus Gemcitabine to Treat Advanced Soft Tissue Sarcoma

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Completed
1/2
28
Europe
Gemcitabine + Rapamycin
Grupo Espanol de Investigacion en Sarcomas
Advanced Soft Tissue Sarcoma
05/13
12/13
NCT01719302: Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma

Completed
1/2
6
US
Gemcitabine, Gemzar, Docetaxel, Taxotere, Pazopanib, Votrient
University of Vermont, Novartis
Stage III Adult Soft Tissue Sarcoma
04/15
04/15
NCT01418001: Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)

Terminated
1/2
5
US
Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination
Memorial Sloan Kettering Cancer Center, National Comprehensive Cancer Network, University of California, Los Angeles, Washington University School of Medicine, Northwestern University
Sarcoma, Leiomyosarcoma, Malignant Peripheral Nerve Sheath Tumor, Malignant Fibrous, Histiocytoma/Undifferentiated Pleomorphic Sarcoma
11/15
11/15
NCT03009058 / 2016-001459-28: Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer

Terminated
1/2
2
Europe
IMM-101, Heat killed M. obuense (NCTC) 13365), Gemcitabine, GEMZAR, Nabpaclitaxel, Abraxane, Capecitabine, Folinic Acid, Leucovorin, Fluorouracil, 5FU, Irinotecan, Campto, Camptosar, Oxaliplatin, Eloxatin, cetuximab, Erbitux, Anti-PD1, pembrolizumab (KEYTRUDA),, nivolumab (OPDIVO), Ipilimumab, YERVOY, Cyclophosphamide, cytophosphane
Immodulon Therapeutics Ltd
Metastatic Cancer
08/17
08/17
PembroPlus, NCT02331251: Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer

Checkmark AACR-NCI-EORTC 2015
Oct 2015 - Oct 2015: AACR-NCI-EORTC 2015
Checkmark IASLC-WCLC 2015
Aug 2015 - Aug 2015: IASLC-WCLC 2015
Terminated
1/2
81
US
Pembrolizumab, Keytruda, Gemcitabine, Gemzar, Docetaxel, Taxotere, Nab-paclitaxel, Abraxane, Vinorelbine, Navelbine, Irinotecan, Camptosar, Liposomal Doxorubicin, Doxil
Western Regional Medical Center
Advanced Cancer, Breast Cancer, Sarcoma, Pancreatic Cancer, Small Cell Lung Cancer, Ovarian
01/18
01/18
NCT03684811: A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

Completed
1/2
93
Europe, US, RoW
FT-2102, Azacitidine, Vidaza, Nivolumab, Opdivo, Gemcitabine and Cisplatin, Gemzar and Platinol
Forma Therapeutics, Inc.
Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme), Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas), Cohort 3a and 3b: Chondrosarcoma, Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma, Cohort 5a: Other Non-Central Nervous System Solid Tumors With IDH1 Mutations
05/21
06/22
NAPAGE, NCT03524898: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma

Terminated
1/2
39
Europe
Nab-Paclitaxel, Abraxane, gemcitabine
Swiss Group for Clinical Cancer Research
Soft Tissue Sarcoma
02/22
02/22
GEMMK, NCT03123276: Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma

Active, not recruiting
1/2
24
Europe
Pembrolizumab, Keytruda, Gemcitabine
Royal Marsden NHS Foundation Trust, Merck Sharp & Dohme LLC
Sarcoma
02/23
02/23
NCT04145700 / 2018-004243-23: CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma

Terminated
1/2
23
Europe, Japan, US, RoW
Ramucirumab, LY3009806, Gemcitabine, Docetaxel
Eli Lilly and Company
Synovial Sarcoma
02/23
02/23
NCT05093322 / 2021-003602-41: A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors

Completed
1/2
13
US
Surufatinib in combination with Gemcitabine, HMPL-012, sulfatinib in combination with Gemcitabine
Hutchmed, HUTCHMED Limited
Solid Tumor, Lymphoma, Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
04/23
04/23
ZN-c3-003, NCT04833582 / 2021-000021-27: A Study of ZN-c3 in Combination With Gemcitabine in Subjects With Osteosarcoma

Active, not recruiting
1/2
84
Europe, US
ZN-c3, Gemcitabine, Gemzar
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Osteosarcoma
08/23
12/23
NCT03997968: A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Active, not recruiting
1/2
170
US
CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine, CYT-0851 in combination with rituximab and bendamustine
Cyteir Therapeutics, Inc.
Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, Head and Neck Cancer, DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma, Pancreatic Cancer, CLL, Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
07/24
12/24
NCT03598595: Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma

Active, not recruiting
1/2
31
US
Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Hydroxychloroquine
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Recurrent Osteosarcoma, Refractory Osteosarcoma
09/24
09/24
NCT04577014: Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma

Active, not recruiting
1/2
67
US
Retifanlimab, INCMGA00012, Gemcitabine, Docetaxel
Memorial Sloan Kettering Cancer Center, Incyte Corporation
Soft Tissue Sarcoma, Sarcoma,Soft Tissue, Sarcoma, Soft Tissue Sarcoma Adult
09/25
09/25
NCT02632448: A Study of LY2880070 in Participants With Advanced or Metastatic Cancer

Recruiting
1/2
229
Europe, Canada, US, RoW
LY2880070, Gemcitabine, Gemzar
Esperas Pharma Inc.
Solid Tumors, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Colon Cancer, Rectal Cancer, Neoplasms, Endometrial Cancer, Soft Tissue Sarcoma, Triple Negative Breast Cancer, Pancreas Cancer, Pancreatic Cancer
09/25
09/25
TINKS, NCT05634369: A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue

Recruiting
1/2
50
US
GEM/DOX + TGFBi expanded NK cells, Docetaxel, Dexamethasone, Pegfilgrastim, Gemcitabine
Nationwide Children's Hospital, National Pediatric Cancer Foundation
Pediatric Sarcoma, Refractory, Pediatric Sarcoma, Relapsed
12/26
12/27

Download Options